Disparities in participation in cancer clinical trials.

N. Bjarnason

DOI: https://doi.org/10.1001/JAMA.292.8.922-A

2004-08-25

Abstract:

What problem does this paper attempt to address?

Robust prediction of gene regulation in colorectal cancer tissues from DNA methylation profiles

Hagen Klett,Yesilda Balavarca,Reka Toth,Biljana Gigic,Nina Habermann,Dominique Scherer,Petra Schrotz-King,Alexis Ulrich,Peter Schirmacher,Esther Herpel,Hermann Brenner,Cornelia M. Ulrich,Karin B. Michels,Hauke Busch,Melanie Boerries

DOI: https://doi.org/10.1080/15592294.2018.1460034

2018-04-03

Epigenetics

Abstract:DNA methylation is recognized as one of several epigenetic regulators of gene expression and as potential driver of carcinogenesis through gene-silencing of tumor suppressors and activation of oncogenes. However, abnormal methylation, even of promoter regions, does not necessarily alter gene expression levels, especially if the gene is already silenced, leaving the exact mechanisms of methylation unanswered. Using a large cohort of matching DNA methylation and gene expression samples of colorectal cancer (CRC; n = 77) and normal adjacent mucosa tissues (n = 108), we investigated the regulatory role of methylation on gene expression. We show that on a subset of genes enriched in common cancer pathways, methylation is significantly associated with gene regulation through gene-specific mechanisms. We built two classification models to infer gene regulation in CRC from methylation differences of tumor and normal tissues, taking into account both gene-silencing and gene-activation effects through hyper- and hypo-methylation of CpGs. The classification models result in high prediction performances in both training and independent CRC testing cohorts (0.92<AUC<0.97) as well as in individual patient data (average AUC = 0.82), suggesting a robust interplay between methylation and gene regulation. Validation analysis in other cancerous tissues resulted in lower prediction performances (0.69<AUC<0.90); however, it identified genes that share robust dependencies across cancerous tissues. In conclusion, we present a robust classification approach that predicts the gene-specific regulation through DNA methylation in CRC tissues with possible transition to different cancer entities. Furthermore, we present HMGA1 as consistently associated with methylation across cancers, suggesting a potential candidate for DNA methylation targeting cancer therapy.

genetics & heredity,biochemistry & molecular biology
Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights

Zhe Liu,Ilias Georgakopoulos-Soares,Nadav Ahituv,Ka-Chun Wong

DOI: https://doi.org/10.1016/j.lfs.2023.121413

IF: 6.78

2023-03-01

Life Sciences

Abstract:Colorectal cancer is a common malignant tumor of the digestive tract. Despite advances in diagnostic techniques and medications. Its prognosis remains challenging. DNA methylation-driven related circulating tumor cells have attracted enormous interest in diagnosing owing to their non-invasive nature and early recognition properties. However, the mechanism through which risk biomarkers act remains elusive. Here, we designed a risk model based on differentially expressed genes, DNA methylation, robust, and survival-related factors in the framework of Cox regression. The model has satisfactory performance and is independently verified by an external and isolated dataset in terms of C-index value, ROC, and tROC. The model was applied to Colorectal cancer patients who were subsequently divided into high- and low-risk groups. Functional annotations, genomic alterations, tumor immune environment, and drug sensitivity were analyzed. We observed that up-regulated genes are associated with epithelial cell differentiation and MAPK signaling pathways. The down-regulated genes are related to IL-7 signaling and apoptosis-induced DNA fragmentation. Interestingly, the immune system was inhibited in high-risk groups. High-frequency mutation genes tend to co-occur. High-risk score patients are related to copy number amplification events. To address the challenges, we suggested eleven and twenty-one drugs that are sensitive to low- and high-risk patients. Finally, an artificial neural network was provided to evaluate the immunotherapeutic efficiency. Taken together, the findings demonstrated that our risk score model is robust and reliable for evaluating the prognosis with novel diagnostic and treatment targets. It also yields benefits for the treatment and provides unique insights into developing therapeutic strategies.

pharmacology & pharmacy,medicine, research & experimental
Abstract IA023: Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer

Peter W. Laird,Nathan J. Spix,Hsiao-yun Milliron,Manpreet Kalkat,Emily Eugster,David Sokol,Emily Jung,Paula Nolte,Kelly K. Krzyzanowski,Toshinori Hinoue,Hui Shen

DOI: https://doi.org/10.1158/1538-7445.canevol23-ia023

IF: 11.2

2024-02-02

Cancer Research

Abstract:Phenotypic plasticity is thought to assist immune evasion, metastasis, and therapeutic resistance in tumor evolution. Epigenetic mechanisms such as DNA methylation provide for a more easily acquired and flexible, yet semi-stable adaptation by the tumor cell than hardwired genetic changes. Cancer-associated gain of DNA methylation at promoter CpG islands or distal regulatory elements is associated with transcriptional silencing, whereas loss of DNA methylation is observed at late-replicating, lamina-attached regions of the genome, tracking with cumulative cell divisions. One of the most well-documented genomic features predisposing to DNA hypermethylation is Polycomb Repressive Complex (PRC) occupancy in precursor cells, consistent with an epigenetic block to cellular differentiation as an early or predisposing event in carcinogenesis. A central question is whether this epigenetic switch from reversible PRC repression to more stable DNA hypermethylation occurs before onset of clonal expansion, or whether it represents an ongoing process during tumor evolution. Clonal expansion is a pivotal characteristic of cancer, and is thought to be initiated by a genetic alteration in a key gatekeeper driver gene. However, not all normal cells appear to be susceptible to malignant transformation following such an event. Multiple lines of evidence suggest that epigenetic heterogeneity among normal cells may affect their cancer-initiating potential. We have developed a tumor processing pipeline to deeply and comprehensively map DNA methylation patterns in primary human colorectal cancer (CRC) and adjacent tissues, while preserving spatial information, enabling inference of the temporal order of molecular alterations. We employ a suite of technologies to map the spatial heterogeneity of DNA methylation patterns in primary human CRC. These include a deep single-cell whole-genome bisulfite sequencing technique that improves genomic coverage several-fold over existing published protocols, providing DNA methylation measurements at the majority of CpGs in the genome in individual tumor cells. We have also calibrated and validated an epigenetic clock that allows us to accurately measure the relative replicative history of individual cells. We infer phylogenetic relationships among subclones, and relate these to their spatial distribution in the primary tumor. We find that some tumors have high proportions of PRC-associated clonal hypermethylation, indicating that these hypermethylation events were already present prior to clonal expansion, possibly contributing to susceptibility to malignant transformation in the cell-of-origin, whereas other tumors appear to have active PRC-associated CpG island hypermethylation ongoing during tumor expansion, generating subclonal heterogeneity, which may influence post-therapeutic recurrence potential. Citation Format: Peter W. Laird, Nathan J. Spix, Hsiao-yun Milliron, Manpreet Kalkat, Emily Eugster, David Sokol, Emily Jung, Paula Nolte, Kelly K. Krzyzanowski, Toshinori Hinoue, Hui Shen. Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr IA023.

oncology
Identifying Differential Methylation in Cancer Epigenetics via a Bayesian Functional Regression Model

Farhad Shokoohi,David A. Stephens,Celia M. T. Greenwood

DOI: https://doi.org/10.3390/biom14060639

IF: 6.064

2024-05-30

Biomolecules

Abstract:DNA methylation plays an essential role in regulating gene activity, modulating disease risk, and determining treatment response. We can obtain insight into methylation patterns at a single-nucleotide level via next-generation sequencing technologies. However, complex features inherent in the data obtained via these technologies pose challenges beyond the typical big data problems. Identifying differentially methylated cytosines (dmc) or regions is one such challenge. We have developed DMCFB, an efficient dmc identification method based on Bayesian functional regression, to tackle these challenges. Using simulations, we establish that DMCFB outperforms current methods and results in better smoothing and efficient imputation. We analyzed a dataset of patients with acute promyelocytic leukemia and control samples. With DMCFB, we discovered many new dmcs and, more importantly, exhibited enhanced consistency of differential methylation within islands and their adjacent shores. Additionally, we detected differential methylation at more of the binding sites of the fused gene involved in this cancer.

biochemistry & molecular biology
Comprehensive analysis of differentially methylated regions in colorectal cancer (CRC).

Omid Solari,Tudor Constantin,Yuqian Jiang,Wengching Chan,Ilker Tunc,Preethi Srinivasan,Misagh Kordi,Marianne Santaguida,Breeana L. Mitchell,Alexey Aleshin,Ryan Swenerton,Joshua Babiarz,Trupti Kawli,Johannes G. Reiter

DOI: https://doi.org/10.1200/jco.2024.42.3_suppl.73

IF: 45.3

2024-01-20

Journal of Clinical Oncology

Abstract:73 Background: Epigenetic alterations have been shown to govern many disease states, including cancer. A key epigenetic mark is the DNA methylation of CpGs. Large studies, like The Cancer Genome Atlas, have shown that DNA methylation can differentiate between cancer status and type. Here, differentially methylated genomic patterns were defined between patients with CRC and healthy individuals by utilizing patterns of co-methylation of adjacent CpG loci. Methods: Deep, whole genome bisulfite sequencing (WGBS) was conducted on DNA samples from 100 healthy individuals (median effective coverage of 352x±38x) and from 75 patients with CRC (median effective coverage of 48x±18x). The two cohorts were chosen to be balanced in terms of age (CRC: 58±11 years; healthy: 57±8 years) and to represent major ethnicities in the USA, and the CRC cohort was chosen to represent all stages, histologies and morphologies, and microsatellite instability (MSI, 23%). A novel machine learning model was developed to discover differentially methylated regions between the healthy and CRC cohorts as well as between subpopulations within the CRC cohort, including age, sex, stage, histology, and MSI vs microsatellite stability (MSS). Results: In total, we discovered 132,911 differentially methylated regions between healthy and CRC cohorts, spanning more than 1.14 million CpGs. 76% of all discovered regions were hypermethylated (70% CpG islands, 1.3% CpG shelves, 21% CpG shores) and the rest were hypomethylated (7.3% CpG islands, 8.6% CpG shelves, 25% CpG shores). We also discovered 220 hypermethylated regions that were differentially methylated between CRC MSI samples and CRC MSS samples and healthy cfDNA samples. Furthermore, we discovered subtype-specific differentially methylated regions, such as 62 hyper-methylated regions that were differentially methylated between mucinous adenocarcinoma samples and the rest of the cohort. Conclusions: Based on deep WGBS data from heterogeneous cohorts, representative of the US population eligible for CRC screening, we identified many differentially methylated regions as strong biomarker candidates for the early detection of cancer. Compared to recurrently mutated driver genes in CRC, we find that differential methylation profiles of CRC samples are generally much more homogenous and are therefore ideal biomarkers for targeted sequencing panels with the purpose of early cancer detection. Further, analysis of these patterns based on clinicopathologic factors enabled discovery of subtype specific markers, which can be incorporated to ensure equivalent performance for underrepresented subtypes or subpopulations.

oncology
A new parsimonious method for classifying Cancer Tissue-of-Origin Based on DNA Methylation 450K data

Shen Jia,Yulin Zhang,Yiming Mao,Jiawei Gao,Yixuan Chen,Yuxuan Jiang,Haochen Luo,Kebo Lv,Jionglong Su

DOI: https://doi.org/10.48550/arXiv.2101.00570

2021-01-03

Tissues and Organs

Abstract:DNA methylation is a well-studied genetic modification that regulates gene transcription of Eukaryotes. Its alternations have been recognized as a significant component of cancer development. In this study, we use the DNA methylation 450k data from The Cancer Genome Atlas to evaluate the efficacy of DNA methylation data on cancer classification for 30 cancer types. We propose a new method for gene selection in high dimensional data(over 450 thousand). Variance filtering is first introduced for dimension reduction and Recursive feature elimination (RFE) is then used for feature selection. We address the problem of selecting a small subsets of genes from large number of methylated sites, and our parsimonious model is demonstrated to be efficient, achieving an accuracy over 91%, outperforming other studies which use DNA micro-arrays and RNA-seq Data . The performance of 20 models, which are based on 4 estimators (Random Forest, Decision Tree, Extra Tree and Support Vector Machine) and 5 classifiers (k-Nearest Neighbours, Support Vector Machine, XGboost, Light GBM and Multi-Layer Perceptron), is compared and robustness of the RFE algorithm is examined. Results suggest that the combined model of extra tree plus catboost classifier offers the best performance in cancer identification, with an overall validation accuracy of 91% , 92.3%, 93.3% and 93.5% for 20, 30, 40 and 50 features respectively. The biological functions in cancer development of 50 selected genes is also explored through enrichment analysis and the results show that 12 out of 16 of our top features have already been identified to be specific with cancer and we also propose some more genes to be tested for future studies. Therefore, our method may be utilzed as an auxiliary diagnostic method to determine the actual clinicopathological status of a specific cancer.
Integrated Analyses of Multi-Omics Reveal Global Patterns of Methylation and Hydroxymethylation and Screen the Tumor Suppressive Roles of HADHB in Colorectal Cancer

Yimin Zhu,Hanlin Lu,Dandan Zhang,Meiyan Li,Xiaohui Sun,Ledong Wan,Dan Yu,Yiping Tian,Hongchuan Jin,Aifen Lin,Fei Gao,Maode Lai

DOI: https://doi.org/10.1186/s13148-018-0458-3

2018-01-01

Clinical Epigenetics

Abstract:Background: DNA methylation is an important epigenetic modification, associated with gene expression. 5-Methylcytosine and 5-hydroxymethylcytosine are two epigenetic hallmarks that maintain the equilibrium of epigenetic reprogramming. Disequilibrium in genomic methylation leads to carcinogenesis. The purpose of this study was to elucidate the epigenetic mechanisms of DNA methylation and hydroxymethylation in the carcinogenesis of colorectal cancer. Methods: Genome-wide patterns of DNA methylation and hydroxymethylation in six paired colorectal tumor tissues and corresponding normal tissues were determined using immunoprecipitation and sequencing. Transcriptional expression was determined by RNA sequencing (RNA-Seq). Groupwise differential methylation regions (DMR), differential hydroxymethylation regions (DhMR), and differentially expressed gene (DEG) regions were identified. Epigenetic biomarkers were screened by integrating DMR, DhMR, and DEGs and confirmed using functional analysis. Results: We identified a genome-wide distinct hydroxymethylation pattern that could be used as an epigenetic biomarker for clearly differentiating colorectal tumor tissues from normal tissues. We identified 59,249 DMRs, 187,172 DhMRs, and 948 DEGs by comparing between tumors and normal tissues. After cross-matching genes containing DMRs or DhMRs with DEGs, we screened seven genes that were aberrantly regulated by DNA methylation in tumors. Furthermore, hypermethylation of the HADHB gene was persistently found to be correlated with downregulation of its transcription in colorectal cancer (CRC). These findings were confirmed in other patients of colorectal cancer. Tumor functional analysis indicated that HADHB reduced cancer cell migration and invasiveness. These findings suggested its possible role as a tumor suppressor gene (TSG). Conclusion: This study reveals the global patterns of methylation and hydroxymethylation in CRC. Several CRC-associated genes were screened with multi-omic analysis. Aberrant methylation and hydroxymethylation were found to be in the carcinogenesis of CRC.
Predicting DNA methylation from genetic data lacking racial diversity using shared classified random effects

J Sunil Rao,Hang Zhang,Erin Kobetz,Melinda C Aldrich,Douglas Conway,J. Sunil Rao,Melinda C. Aldrich

DOI: https://doi.org/10.1016/j.ygeno.2020.10.036

IF: 4.31

2021-01-01

Genomics

Abstract:<p>Public genomic repositories are notoriously lacking in racially and ethnically diverse samples. This limits the reaches of exploration and has in fact been one of the driving factors for the initiation of the All of Us project. Our particular focus here is to provide a model-based framework for accurately predicting DNA methylation from genetic data using racially sparse public repository data. Epigenetic alterations are of great interest in cancer research but public repository data is limited in the information it provides. However, genetic data is more plentiful. Our phenotype of interest is cervical cancer in The Cancer Genome Atlas (TCGA) repository. Being able to generate such predictions would nicely complement other work that has generated gene-level predictions of gene expression for normal samples.</p><p>We develop a new prediction approach which uses shared random effects from a nested error mixed effects regression model. The sharing of random effects allows borrowing of strength across racial groups greatly improving predictive accuracy. Additionally, we show how to further borrow strength by combining data from different cancers in TCGA even though the focus of our predictions is DNA methylation in cervical cancer. We compare our methodology against other popular approaches including the elastic net shrinkage estimator and random forest prediction. Results are very encouraging with the shared classified random effects approach uniformly producing more accurate predictions – overall and for each racial group.</p>

genetics & heredity,biotechnology & applied microbiology
Genome-wide Analysis of Aberrant DNA Methylation for Identification of Potential Biomarkers in Colorectal Cancer Patients.

Wei-Jia Fang,Yi Zheng,Li-Ming Wu,Qing-Hong Ke,Hong Shen,Ying Yuan,Shu-Sen Zheng

DOI: https://doi.org/10.7314/apjcp.2012.13.5.1917

2012-01-01

Asian Pacific Journal of Cancer Prevention

Abstract:BACKGROUND:Colorectal cancer is one of the leading causes of mortality worldwide. Genome wide analysis studies have identified sequence mutations causing loss-of-function that are associated with disease occurrence and severity. Epigenetic modifications, such DNA methylation, have also been implicated in many cancers but have yet to be examined in the East Asian population of colorectal cancer patients.METHODS:Biopsies of tumors and matched non-cancerous tissue types were obtained and genomic DNA was isolated and subjected to the bisulphite conversion method for comparative DNA methylation analysis on the Illumina Infinium HumanMethylation27 BeadChip.RESULTS:Totals of 258 and 74 genes were found to be hyper- and hypo-methylated as compared to the individual's matched control tissue. Interestingly, three genes that exhibited hypermethylation in their promoter regions, CMTM2, ECRG4, and SH3GL3, were shown to be significantly associated with colorectal cancer in previous studies. Using heatmap cluster analysis, eight hypermethylated and 10 hypomethylated genes were identified as significantly differentially methylated genes in the tumour tissues.CONCLUSIONS:Genome-wide methylation profiling facilitates rapid and simultaneous analysis of cancerous cells which may help to identify methylation markers with high sensitivity and specificity for diagnosis and prognosis. Our results show the promise of the microarray technology in identification of potential methylation biomarkers for colorectal cancers.
Identification of DNA methylation characteristics associated with metastasis and prognosis in colorectal cancer

DOI: https://doi.org/10.1186/s12920-024-01898-4

2024-05-11

BMC Medical Genomics

Abstract:Colorectal cancer (CRC) is prone to metastasis and recurrence after surgery, which is one of the main causes for its poor treatment and prognosis. Therefore, it is essential to identify biomarkers associated with metastasis and recurrence in CRC. DNA methylation has a regulatory role in cancer metastasis, tumor immune microenvironment (TME), and prognosis and may be one of the most valuable biomarkers for predicting CRC metastasis and prognosis. We constructed a diagnostic model and nomogram that can effectively predict CRC metastasis based on the differential methylation CpG sites (DMCs) between metastatic and non-metastatic CRC patients. Then, we identified 17 DMCs associated with progression free survival (PFS) of CRC and constructed a prognostic model. The prognosis model based on 17 DMCs can predict the PFS of CRC with medium to high accuracy. The results of immunohistochemical analysis indicated that the protein expression levels of the genes involved in prognostic DMCs were different between normal and colorectal cancer tissues. According to the results of immune-related analysis, we found that the low-risk patients had better immunotherapy response. In addition, high risk scores were negatively correlated with high tumor mutation burden (TMB) levels, and patients with low TMB levels in the high-risk group had the worst PFS. Our work shows the clinical value of DNA methylation in predicting CRC metastasis and PFS, as well as their correlation with TME, immunotherapy, and TMB, which helps understand the changes of DNA methylation in CRC metastasis and improving the treatment and prognosis of CRC.

genetics & heredity
Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer

Alexander Kel,Ulyana Boyarskikh,Philip Stegmaier,Leonid S Leskov,Andrey V Sokolov,Ivan Yevshin,Nikita Mandrik,Daria Stelmashenko,Jeannette Koschmann,Olga Kel-Margoulis,Mathias Krull,Anna Martínez-Cardús,Sebastian Moran,Manel Esteller,Fedor Kolpakov,Maxim Filipenko,Edgar Wingender

DOI: https://doi.org/10.1186/s12859-019-2687-7

IF: 3.307

2019-04-18

BMC Bioinformatics

Abstract:Background: The search for molecular biomarkers of early-onset colorectal cancer (CRC) is an important but still quite challenging and unsolved task. Detection of CpG methylation in human DNA obtained from blood or stool has been proposed as a promising approach to a noninvasive early diagnosis of CRC. Thousands of abnormally methylated CpG positions in CRC genomes are often located in non-coding parts of genes. Novel bioinformatic methods are thus urgently needed for multi-omics data analysis to reveal causative biomarkers with a potential driver role in early stages of cancer. Methods: We have developed a method for finding potential causal relationships between epigenetic changes (DNA methylations) in gene regulatory regions that affect transcription factor binding sites (TFBS) and gene expression changes. This method also considers the topology of the involved signal transduction pathways and searches for positive feedback loops that may cause the carcinogenic aberrations in gene expression. We call this method "Walking pathways", since it searches for potential rewiring mechanisms in cancer pathways due to dynamic changes in the DNA methylation status of important gene regulatory regions ("epigenomic walking"). Results: In this paper, we analysed an extensive collection of full genome gene-expression data (RNA-seq) and DNA methylation data of genomic CpG islands (using Illumina methylation arrays) generated from a sample of tumor and normal gut epithelial tissues of 300 patients with colorectal cancer (at different stages of the disease) (data generated in the EU-supported SysCol project). Identification of potential epigenetic biomarkers of DNA methylation was performed using the fully automatic multi-omics analysis web service "My Genome Enhancer" (MGE) (my-genome-enhancer.com). MGE uses the database on gene regulation TRANSFAC®, the signal transduction pathways database TRANSPATH®, and software that employs AI (artificial intelligence) methods for the analysis of cancer-specific enhancers. Conclusions: The identified biomarkers underwent experimental testing on an independent set of blood samples from patients with colorectal cancer. As a result, using advanced methods of statistics and machine learning, a minimum set of 6 biomarkers was selected, which together achieve the best cancer detection potential. The markers include hypermethylated positions in regulatory regions of the following genes: CALCA, ENO1, MYC, PDX1, TCF7, ZNF43.
Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A prospective randomized clinical trial.

Jin-Seok Kim,S. Shin,J. Na,C. Choi,Seong Hwan Kim,Jin Won Kim,E. Kim,S. Rha,C. Park,H. Seo,D. Oh,C. Hwang,H. Lim

DOI: https://doi.org/10.1016/j.ijcard.2014.12.035

IF: 4.039

2015-02-15

International Journal of Cardiology

Abstract:
Exploring the DNA methylome of Korean patients with colorectal cancer consolidates the clinical implications of cancer-associated methylation markers

Sejoon Lee,Kil-yong Lee,Ji-Hwan Park,Duck-Woo Kim,Heung-Kwon Oh,Seong-Taek Oh,Jongbum Jeon,Dongyoon Lee,Soobok Joe,Hoang Bao Khanh Chu,Jisun Kang,Jin-Young Lee,Sheehyun Cho,Hyeran Shim,Si-Cho Kim,Hong Seok Lee,Young-Joon Kim,Jin Ok Yang,Jaeim Lee,Sung-Bum Kang

DOI: https://doi.org/10.5483/bmbrep.2023-0103

2024-03-12

BMB Reports

Abstract:Aberrant DNA methylation plays a critical role in the development and progression of colorectal cancer (CRC), which has high incidence and mortality rates in Korea. Various CRC-associated methylation markers for cancer diagnosis and prognosis have been developed; however, they have not been validated for Korean patients owing to the lack of comprehensive clinical and methylome data. Here, we obtained reliable methylation profiles for 228 tumor, 103 adjacent normal, and two unmatched normal colon tissues from Korean patients with CRC using an Illumina Infinium EPIC array; the data were corrected for biological and experiment biases. A comparative methylome analysis confirmed the previous findings that hypermethylated positions in the tumor were highly enriched in CpG island and promoter, 5' untranslated, and first exon regions. However, hypomethylated positions were enriched in the open-sea regions considerably distant from CpG islands. After applying a CpG island methylator phenotype (CIMP) to the methylome data of tumor samples to stratify the CRC patients, we consolidated the previously established clinicopathological findings that the tumors with high CIMP signatures were significantly enriched in the right colon. The results showed a higher prevalence of microsatellite instability status and MLH1 methylation in tumors with high CMP signatures than in those with low or non-CIMP signatures. Therefore, our methylome analysis and dataset provide insights into applying CRC-associated methylation markers for Korean patients regarding cancer diagnosis and prognosis. [BMB Reports 2024; 57(3): 161-166].

biochemistry & molecular biology
DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden

Hao Huang,Weifan Cao,Zhiping Long,Lei Kuang,Xi Li,Yifei Feng,Yuying Wu,Yang Zhao,Yinggang Chen,Peng Sun,Panxin Peng,Jinli Zhang,Lijun Yuan,Tianze Li,Huifang Hu,Gairui Li,Longkun Yang,Xing Zhang,Fulan Hu,Xizhuo Sun,Dongsheng Hu

DOI: https://doi.org/10.3389/fonc.2022.1030335

IF: 4.7

2023-01-13

Frontiers in Oncology

Abstract:Background Immune checkpoint inhibitor (ICI) therapy has proven to be a promising treatment for colorectal cancer (CRC). We aim to investigate the relationship between DNA methylation and tumor mutation burden (TMB) by integrating genomic and epigenetic profiles to precisely identify clinical benefit populations and to evaluate the effect of ICI therapy. Methods A total of 536 CRC tissues from the Cancer Genome Atlas (TCGA) with mutation data were collected and subjected to calculate TMB. 80 CRC patients with high TMB and paired normal tissues were selected as training sets and developed the diagnostic and prognostic methylation models, respectively. In the validation set, the diagnostic model was validated in our in-house 47 CRC tissues and 122 CRC tissues from the Gene Expression Omnibus (GEO) datasets, respectively. And a total of 38 CRC tissues with high TMB from the COLONOMICS dataset verified the prognostic model. Results A positive correlation between differential methylation positions and TMB level was observed in TCGA CRC cohort (r=0.45). The diagnostic score that consisted of methylation levels of four genes ( ADHFE1 , DOK6 , GPR75 , and MAP3K14-AS1 ) showed high diagnostic performance in the discovery (AUC=1.000) and two independent validation (AUC=0.946, AUC=0.857) datasets. Additionally, these four genes showed significant positive correlations with NK cells. The prognostic score containing three genes ( POU3F3 , SYN2 , and TMEM178A ) had significantly poorer survival in the high-risk TMB samples than those in the low-risk TMB samples ( P =0.016). CRC patients with low-risk scores combined with TMB levels represent a favorable survival. Conclusions By integrating analyses of methylation and mutation data, it is suggested that DNA methylation patterns combined with TMB serve as a novel potential biomarker for early screening in more high-TMB populations and for evaluating the prognostic effect of CRC patients with ICI therapy.

oncology
Abstract B033: Mapping subclonal epigenetic evolution in colorectal cancer by spatial analysis of DNA hypermethylation

Nathan J. Spix,Hsiao-yun Milliron,Manpreet Kalkat,Emily Eugster,David W. Chesla,David Sokol,Emily Jung,Paula Nolte,Kelly K. Krzyzanowski,Toshinori Hinoue,Hui Shen,Peter W. Laird

DOI: https://doi.org/10.1158/1538-7445.canevol23-b033

IF: 11.2

2024-02-02

Cancer Research

Abstract:Aberrant patterns of DNA methylation (DNAme) have long been noted in colorectal cancer (CRC). Early studies found overall hypomethylation of the cancer genome, while subsequent work revealed focal hypermethylation at specific loci, especially CpG-rich promoters. Loci occupied by polycomb repressive complex 2 in stem cells are remarkably enriched in cancer-specific hypermethylation events. These Polycomb Target Genes (PTGs) include important transcriptional regulators of lineage specification and differentiation, suggesting that hypermethylation-mediated silencing of PTGs could play an active role in CRC initiation or progression. Despite these findings, we have limited knowledge of when, where, and how this hypermethylation arises. Preliminary evidence from bulk tumor samples in the Cancer Genome Atlas suggests that many of these PTG hypermethylation events may be almost completely clonal. Additionally, we have noted rare, densely methylated reads covering PTGs in cancer-adjacent, histologically normal tissue. These observations suggest that PTG hypermethylation may be a very early event in carcinogenesis and may play a permissive or even active role in that process. To better understand the timing and evolution of PTG hypermethylation events in CRC, we have developed a protocol that allows us to extract dozens of small (20μL), spatially annotated mini-bulk samples from live tumors. These mini-bulks may be frozen or dissociated to viable single-cell suspensions. Remaining tumor tissue is preserved in the form of spatially annotated FFPE blocks, which can be used for analyses such as high-plex immunofluorescence or spatial transcriptomics. Using this process, we have collected over 500 spatially annotated samples from 6 CRC cases, including 196 micro-bulk samples profiled using the Infinium MethylationEPIC array. Additionally, we have profiled DNAme in 147 single cells using a dramatically improved single-cell whole-genome bisulfite sequencing protocol developed in our lab. Analysis of EPIC array data reveals wide variation in DNAme heterogeneity between tumors. While in some tumors, the vast majority of DNA hypermethylation events are clonal, other tumors reveal significant intra-tumor heterogeneity, including two or more prominent DNAme subclones as well as a substantial number of 'private' hypermethylation events that occur in only one sample. Mapping DNAme information back onto our spatial data reveals that in at least one case, DNAme clones are spatially partitioned and are associated with distinct histology. Ongoing work includes inference of phylogenetic trees from DNA hypermethylation events using non-reversible models of methylation accumulation, allowing us to measure the relative timing of hypermethylation events, as well as integration of array, whole-genome, and single-cell methylation data to more completely characterize DNAme subclones, characterize cellular DNAme heterogeneity at variably methylated sites, and shed further light on the evolution of cancer-related DNA hypermethylation. Citation Format: Nathan J. Spix, Hsiao-yun Milliron, Manpreet Kalkat, Emily Eugster, David W. Chesla, David Sokol, Emily Jung, Paula Nolte, Kelly K. Krzyzanowski, Toshinori Hinoue, Hui Shen, Peter W. Laird. Mapping subclonal epigenetic evolution in colorectal cancer by spatial analysis of DNA hypermethylation [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Translating Cancer Evolution and Data Science: The Next Frontier; 2023 Dec 3-6; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_2) nr B033.

oncology
DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation

Rajbir Nath Batra,Aviezer Lifshitz,Ana Tufegdzic Vidakovic,Suet-Feung Chin,Ankita Sati-Batra,Stephen-John Sammut,Elena Provenzano,H. Raza Ali,Ali Dariush,Alejandra Bruna,Leigh Murphy,Arnie Purushotham,Ian Ellis,Andrew Green,Francine E. Garrett-Bakelman,Chris Mason,Ari Melnick,Samuel A. J. R. Aparicio,Oscar M. Rueda,Amos Tanay,Carlos Caldas

DOI: https://doi.org/10.1038/s41467-021-25661-w

IF: 16.6

2021-09-13

Nature Communications

Abstract:Abstract DNA methylation is aberrant in cancer, but the dynamics, regulatory role and clinical implications of such epigenetic changes are still poorly understood. Here, reduced representation bisulfite sequencing (RRBS) profiles of 1538 breast tumors and 244 normal breast tissues from the METABRIC cohort are reported, facilitating detailed analysis of DNA methylation within a rich context of genomic, transcriptional, and clinical data. Tumor methylation from immune and stromal signatures are deconvoluted leading to the discovery of a tumor replication-linked clock with genome-wide methylation loss in non-CpG island sites. Unexpectedly, methylation in most tumor CpG islands follows two replication-independent processes of gain (MG) or loss (ML) that we term epigenomic instability. Epigenomic instability is correlated with tumor grade and stage, TP53 mutations and poorer prognosis. After controlling for these global trans-acting trends, as well as for X-linked dosage compensation effects, cis -specific methylation and expression correlations are uncovered at hundreds of promoters and over a thousand distal elements. Some of these targeted known tumor suppressors and oncogenes. In conclusion, this study demonstrates that global epigenetic instability can erode cancer methylomes and expose them to localized methylation aberrations in-cis resulting in transcriptional changes seen in tumors.

multidisciplinary sciences
A Bayesian framework for genome-wide inference of DNA methylation levels

Marcel Hirt,Axel Finke,Alexandros Beskos,Petros Dellaportas,Stephan Beck,Ismail Moghul,Simone Ecker

DOI: https://doi.org/10.48550/arXiv.2211.07311

2022-11-14

Applications

Abstract:DNA methylation is an important epigenetic mark that has been studied extensively for its regulatory role in biological processes and diseases. WGBS allows for genome-wide measurements of DNA methylation up to single-base resolutions, yet poses challenges in identifying significantly different methylation patterns across distinct biological conditions. We propose a novel methylome change-point model which describes the joint dynamics of methylation regimes of a case and a control group and benefits from taking into account the information of neighbouring methylation sites among all available samples. We also devise particle filtering and smoothing algorithms to perform efficient inference of the latent methylation patterns. We illustrate that our approach can detect and test for very flexible differential methylation signatures with high power while controlling Type-I error measures.
Abstract 3496: EpigenPlot: A tool for the gene-level methylation analysis of colorectal tumors

Dalma Müller,Balazs Gyorffy

DOI: https://doi.org/10.1158/1538-7445.am2024-3496

IF: 11.2

2024-03-31

Cancer Research

Abstract:Introduction. Aberrant DNA methylation patterns are frequent in colorectal adenocarcinoma (CRC) tissues. The investigation of this layer of epigenetic regulation holds the promise of a better understanding of tumour progression and the identification of novel biomarker candidates. Purpose. Our goal was to collect and analyse publicly available DNA methylation data of colorectal samples and create a user-friendly tool for exploring and visualizing the CRC methylome. Methods. We used Illumina Infinium Methylation Arrays, which is a popular platform for genome-wide methylation analysis of large cohorts. Gene Expression Omnibus database (GEO) and TCGA-COAD (The Cancer Genome Atlas Colon Adenocarcinoma) datasets including normal colorectal mucosa, adenoma, and adenocarcinoma samples were systematically collected and filtered. Differentially methylated regions were identified using the Kruskal-Wallis test. Genes with significant methylation changes were further analysed using ROC (Receiver Operator Characteristic) analysis. Finally, we established a web application using the shiny R package. Results. We assembled a database including methylation data of 2,586 samples. Adenoma and adenocarcinoma samples were globally hypomethylated. Hypermethylation (p = 0.2) in adenocarcinoma samples was predominantly present in regions near proximal promoters. Out of the 74 previously proposed biomarkers examined, 50 had a cross-validated AUC of over 0.8. FDA-approved biomarkers BMP3, NDRG4, and SEPT9 have shown the highest performance in the TSS200 region (cvAUC = 0.8, 0.83, and 0.76, respectively). Genes with the highest performance were ITGA4 (5'UTR, first exon: cvAUC = 0.9), MDFI (5'UTR: cvAUC = 0.9), CNRIP1 (5'UTR, first exon: cvAUC = 0.89). The established web application can visualize methylation at CpG sites and gene regions, and KEGG pathway genes. The platform is available at https://epigenplot.com. Conclusion. We collected and analysed a sizeable database of colorectal tissue data. Gene regions with the best performance include previously proposed and novel diagnostic biomarker candidates. The web platform provides an tool for the efficient exploration of the assembled data. Citation Format: Dalma Müller, Balazs Gyorffy. EpigenPlot: A tool for the gene-level methylation analysis of colorectal tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3496.

oncology
Texas Res-X and rhodamine Red-X, new derivatives of sulforhodamine 101 and lissamine rhodamine B with improved labeling and fluorescence properties.

C. Lefevre,H. Kang,R. Haugland,Nabi Malekzadeh,S. Arttamangkul,R. Haugland

DOI: https://doi.org/10.1021/BC960034P

IF: 4.7

1996-07-25

Bioconjugate Chemistry

Abstract:Texas Red sulfonyl chloride (TR-SC) and Lissamine rhodamine B sulfonyl chloride (LRB-SC) are popular dyes often used to prepare red fluorescent conjugates that are useful second labels in combination with fluorescein. Unfortunately, being sulfonyl chloride derivatives, both are unstable to moisture during storage and prone to hydrolysis in the conjugation reaction. Their instability causes the percentage of reactive dye to vary from lot to lot and requires use of low temperatures and a relatively high pH to optimize conjugation efficiency. Succinimidyl esters of the aminohexanoic acid sulfonamides of both dyes have been prepared, which are designated Texas Red-X succinimidyl ester (TR-X-SE) and Rhodamine Red-X succinimidyl ester, respectively. Their spectral properties are similar to those of their sulfonyl chloride analogs; moreover, incorporation of the succinimidyl ester at the end of the aliphatic chain spacer facilitates conjugation, decreases precipitation of proteins during conjugation and storage, and usually increases the fluorescence yield of the conjugate. Comparison of the rate of hydrolysis of TR-SC with that of TR-X-SE shows that, while the former was completely hydrolyzed within 5 min by exposure to water, TR-X-SE retains most of its reactivity for more than an hour. The reactivity of both new derivatives is high between pH 7.5 and 8.5, allowing conjugation of proteins that do not tolerate the high pH required for reaction with sulfonyl chlorides. In addition, Texas Red maleimides and haloacetamides containing spacer groups were prepared for labeling sulfhydryl groups. A Texas Red-X derivative of phalloidin has also been prepared, and its use for labeling F-actin has been characterized.
DNA methylation arrays as surrogate measures of cell mixture distribution

Eugene Andres Houseman,William P Accomando,Devin C Koestler,Brock C Christensen,Carmen J Marsit,Heather H Nelson,John K Wiencke,Karl T Kelsey

DOI: https://doi.org/10.1186/1471-2105-13-86

IF: 3.307

2012-05-08

BMC Bioinformatics

Abstract:BackgroundThere has been a long-standing need in biomedical research for a method that quantifies the normally mixed composition of leukocytes beyond what is possible by simple histological or flow cytometric assessments. The latter is restricted by the labile nature of protein epitopes, requirements for cell processing, and timely cell analysis. In a diverse array of diseases and following numerous immune-toxic exposures, leukocyte composition will critically inform the underlying immuno-biology to most chronic medical conditions. Emerging research demonstrates that DNA methylation is responsible for cellular differentiation, and when measured in whole peripheral blood, serves to distinguish cancer cases from controls.ResultsHere we present a method, similar to regression calibration, for inferring changes in the distribution of white blood cells between different subpopulations (e.g. cases and controls) using DNA methylation signatures, in combination with a previously obtained external validation set consisting of signatures from purified leukocyte samples. We validate the fundamental idea in a cell mixture reconstruction experiment, then demonstrate our method on DNA methylation data sets from several studies, including data from a Head and Neck Squamous Cell Carcinoma (HNSCC) study and an ovarian cancer study. Our method produces results consistent with prior biological findings, thereby validating the approach.ConclusionsOur method, in combination with an appropriate external validation set, promises new opportunities for large-scale immunological studies of both disease states and noxious exposures.

biochemical research methods,biotechnology & applied microbiology,mathematical & computational biology

Disparities in participation in cancer clinical trials.

Robust prediction of gene regulation in colorectal cancer tissues from DNA methylation profiles

Risk scoring based on DNA methylation-driven related DEGs for colorectal cancer prognosis with systematic insights

Abstract IA023: Spatial reconstruction and temporal inference of DNA methylation alterations in primary human colorectal cancer

Identifying Differential Methylation in Cancer Epigenetics via a Bayesian Functional Regression Model

Comprehensive analysis of differentially methylated regions in colorectal cancer (CRC).

A new parsimonious method for classifying Cancer Tissue-of-Origin Based on DNA Methylation 450K data

Integrated Analyses of Multi-Omics Reveal Global Patterns of Methylation and Hydroxymethylation and Screen the Tumor Suppressive Roles of HADHB in Colorectal Cancer

Predicting DNA methylation from genetic data lacking racial diversity using shared classified random effects

Genome-wide Analysis of Aberrant DNA Methylation for Identification of Potential Biomarkers in Colorectal Cancer Patients.

Identification of DNA methylation characteristics associated with metastasis and prognosis in colorectal cancer

Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer

Does isolation of the left atrial posterior wall improve clinical outcomes after radiofrequency catheter ablation for persistent atrial fibrillation?: A prospective randomized clinical trial.

Exploring the DNA methylome of Korean patients with colorectal cancer consolidates the clinical implications of cancer-associated methylation markers

DNA methylation-based patterns for early diagnostic prediction and prognostic evaluation in colorectal cancer patients with high tumor mutation burden

Abstract B033: Mapping subclonal epigenetic evolution in colorectal cancer by spatial analysis of DNA hypermethylation

DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation

A Bayesian framework for genome-wide inference of DNA methylation levels

Abstract 3496: EpigenPlot: A tool for the gene-level methylation analysis of colorectal tumors

Texas Res-X and rhodamine Red-X, new derivatives of sulforhodamine 101 and lissamine rhodamine B with improved labeling and fluorescence properties.

DNA methylation arrays as surrogate measures of cell mixture distribution